Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

NCT03604536 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2022-03-09

No results posted yet for this study

Summary

This study investigates the effect of individualized monotherapy with Mesalazine (Pentasa Sachet ®) on time to remission in patients with mild to moderate UC in an eHealth setting.

Conditions

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY
  • Nordsjaellands Hospital

    lead OTHER

Principal Investigators

  • Pia Munkholm, Prof · North Zealand University Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-08-31
Completion
2021-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03604536 on ClinicalTrials.gov